Marisa Dolled‐Filhart

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst, Paul Baas, Dong‐Wan Kim et al. · The Lancet · 2015 · 6.4K citations

Pembrolizumab Versus Docetaxel, Oncology, Clinical Trials +7

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.1K citations · Full text

X-Tile

Robert L. Camp, Marisa Dolled‐Filhart, David L. Rimm · Clinical Cancer Research · 2004 · 3.9K citations

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

Laura Q.M. Chow, Robert I. Haddad, Shilpa Gupta et al. · Journal of Clinical Oncology · 2016 · 846 citations · Full text

Antitumor Activity, Immunology, Pathology +16

Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

Adil Daud, Jedd D. Wolchok, Caroline Robert et al. · Journal of Clinical Oncology · 2016 · 661 citations · Full text

Immunology, Cell Death, Pathology +18